A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study

Inclusion Criteria: * Patients 9 to 18 years of age who completed visit 33 (week 104) of WA19977 study with at least JIA ACR30 clinical response to RoActemra/Actemra relative to baseline in WA19977, with no AEs, SAEs or conditions that lead to unacceptable risk of continued treatment * Scheduled to receive first RoActemra/Actemra infusion in this study between 4 and 6 weeks after the last IV infusion in the core study * Females of child-bearing potential and males with female partners of child-bearing potential must agree to use effective contraception as defined by protocol Exclusion Criteria: * Patients with, according to investigator judgment, not satisfactory benefit from RoActemra/Actemra therapy within WA19977 * Treatment with any investigational agent since the last administration of study drug in the core study WA19977 or current participation in another clinical trial except WA19977 * Patient developed any other autoimmune rheumatic disease or overlap syndrome other than the permitted polyarticular-course JIA subsets: rheumatoid factor positive or negative JIA or extended oligoarticular JIA * Patient is pregnant , lactating, or intending to become pregnant during the study and up to 12 weeks after the last administration of study drug * Any significant concomitant disease or medical or surgical condition * History of significant allergic or infusion reactions to prior biologic therapy * Known current active acute, subacute, chronic or history of recurrent infectio…